Abstract submissions are now open!

The 15th Asia Oceania ORL-HNS Congress (AO ORL-HNS 2023) invites you to submit an abstract for possible inclusion in the official congress program. 

Detailed information on how to submit your abstract is included below. 

Accepted abstracts will be included in the official 2023 Congress program. 

Important dates:

Please diarise the following important program dates. 

Submission opens: June 2022
Submission deadline: 20 October 2022
Author notifications: late November

Please contact program@orlhns23.com if you have any questions regarding your submission or the program in general. 

Before submitting your abstract, ensure you read the below guidelines carefully – all information that you require is included below. 

Presentation formats

Abstracts can be submitted for either oral or poster presentations. 

Oral presentations
Oral presentations will be asked to present an oral presentation at the congress including a PowerPoint presentation and Q&A with the audience. 

Poster presentations
Poster presentations will be asked to present a visual poster display and potentially participate in a guided poster tour at the congress. 

Abstract submission guidelines

  • All submissions must be in English. English is the official congress language and all presentations must also be in English
  • Submission titles must not be longer than 20 words and should be brief and explicit
  • Submissions must not exceed 300 words, be clear and concise, highlight relevant aspects, findings and conclusions
  • Should you exceed the 300 word limit, the excess limit will NOT appear in the meeting publication
  • Abbreviations should be used only in common terms. For uncommon terms, the abbreviation should be given in brackets after the first full use of the word
  • The abstract title, section headings, author information are not included in the overall word count
  • Abstracts should follow the following format: aims/methodology/results/conclusion
  • Tables, diagrams, graphs etc CANNOT be accepted in the abstract submission. 
  • Acceptance/timing/presentation/discussion of all papers and posters are at the discretion of the Scientific Committee. 
  • Notification of acceptance/timing/presentation/discussion will be included in email correspondence sent to the submitting author
  • Bullying, harassment, and inappropriate racial, gender or sexual comments will not be accepted at the congress

Please enter submission information carefully, information will be published exactly as submitted. 

All abstract submissions must be received online through the abstract submission portal

Abstract submission themes

Abstracts can be submitted under any of the below themes:

  • ENT physicians
  • Facial plastics
  • Head and neck
  • Indigenous health
  • Laryngology
  • Neuro-otology
  • Otology
  • Paediatric
  • Rhinology
  • Salivary gland
  • Skull base
  • Sleep
  • Thyroid/Parathyoid
  • Translational research day – artificial intelligence
  • Translational research day – immunotherapy
  • Other

Abstract review information

  • All submitted abstracts will be peer reviewed by a subsection of the APLAR 2022 Scientific Committee
  • Incomplete abstracts or abstracts not written in English cannot be processed and will not be reviewed
  • No revisions are possible after the submission deadline – no exceptions

Conditions of acceptance

If accepted into the official program, the following conditions will apply:

  • Oral presentations can only be presented by one author
  • Presenters must be a listed author on the submission
  • Accepted presenters must register, pay and attend the congress; otherwise the abstract will not be included in the official program
  • Abstract submissions remain the property of ORL-HNS and the Scientific Committee reserves the right to publish and distribute

Terms and conditions

  • Submitting author hereby commits with the present data protection and privacy policy
  • Submitting authors declare that the submission is the original work of at least one author/presenter
  • No funding is provided to accepted presenters
  • Submitting authors must declare the work described in the abstract has appropriate approval under local, ethical and animal experimentation rules
  • Submitting authors must declare that their work does not conflict with any existing copyright agreements with alternate publishers
  • Submitting authors provide consent for their presentation materials to be used to assist with promoting AO ORL-HNS 2023, future ORL-HNS congresses and on-demand content

Have any questions?

If you have any questions regarding abstract submissions, the program or the congress as a whole, please contact the AO ORL-HNS Program Manager

Dr Seiji Kakehata

Yamagata University Faculty of Medicine

Seiji Kakehata, M.D., Ph.D.is best known for his work in pioneering endoscopic ear surgery in his home country of Japan and around the world. He servesas Professor and Chair of the Department of Otorhinolaryngology-Headand Neck Surgery at Yamagata University Faculty of Medicine. He is the Chair of Board of Directors, Japan Otological Society (JOS). In addition, he is a founding board member of the International Working Group on Endoscopic Ear Surgery(IWGEES) and its presidentelectas well as the president of the Pan-Asia Working Group on Endoscopic Ear Surgery (PAWGEES).

Dr. Kakehata’s clinical interests includeminimally invasive endoscopicear surgery, conductive and sensorineural hearing loss,and facial nervepalsy.Dr. Kakehata’s research has focused on cochlear hair cell physiology and hearing regeneration. His funded research includes the study of outer hair cell motility, effects of cholesterol alterationson outer hair cells, regenerationof the facial nerve, and regeneration of auditory nerve fiber growth and synapse formation after ear injury.

Dr. Kakehata organized and held the first courses in endoscopic earsurgery in Asia and has held anannual hands-on course since 2012. He has presented at numerous regionaland national meetings in Japan as well as international meetings and courses especially on the subject of endoscopic ear surgery. He has published approximately 150 articles and book chapters.

Dr Dana Thompson

Ann & Robert H. Lurie Children’s Hospital of Chicago


Dr. Thompson is the Lauren D. Holinger Professor Chair of Pediatric Otolaryngology at the Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine. She has held faculty positions as premier institutions including the Mayo Clinic and University of Cincinnati College of Medicine/Cincinnati Children’s Hospital. In 2011 she achieved the academic rank of Professor, making her the first African American woman professor in the specialty of Otolaryngology Head and Neck Surgery in the United States. She brings 23 years of experience as an internationally recognized airway surgeon and leader in aerodigestive medicine. The collective research contributions in laryngomalacia have influenced the surgical and medical management of the disease and she is considered one of the world’s authorities on the topic. She received the prestigious Mosher Award from the Triological Society for excellence in clinical research for her seminal work elucidating the etiology of Laryngomalacia.

Prof Sarah Wise

Emory University School of Medicine

Sarah K. Wise, MD, MSCR is Professor of Otolaryngology-Head and Neck Surgery at Emory University in Atlanta, Georgia. She is the Emory Otolaryngology Residency Program Director, Rhinology Fellowship Director, and Director of Otolaryngic Allergy. Dr. Wise completed medical school at the University of Texas Health Science Center San Antonio, residency at Emory University and rhinology fellowship at the Medical University of South Carolina. Dr. Wise has served on the Board of Directors of the American Rhinologic Society and the American Academy of Otolaryngic Allergy. She will become President of the American Rhinologic Society in September 2022, serving as the Society’s first female president. Her clinical interests include inflammatory rhinology, otolaryngic allergy, relationship of allergy and chronic rhinosinusitis, and cerebrospinal fluid leaks. Dr. Wise lectures nationally and internationally. Her most notable publication is the International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis, where she served as first author/primary editor.



Lorem ipsum dolor sit amet. Aut officia facilis sit animi voluptatum ut voluptatem nisi rem omnis quia. Vel libero minima et totam officia non rerum sequi sunt impedit sit aliquid neque rem mollitia sint non iste voluptatum. Et distinctio sequi aut voluptatem provident in maxime esse cum velit quia a asperiores harum in error deserunt qui repellat vero. Ut voluptatem animi et voluptates quidem ut rerum dolor aut libero perspiciatis.

Prof Robert Ferris

UPMC Hillman Cancer Center

Robert L. Ferris, MD, PhD is Hillman Professor of Oncology and Director of the UPMC Hillman Cancer Center. He is Associate Vice Chancellor for Cancer Research, and Professor of Otolaryngology, of Immunology, and of Radiation Oncology at the University of Pittsburgh. As a head and neck surgical oncologist and translational tumor immunologist, his lab is uniquely positioned to investigate mechanisms of anti-tumor immunity in the tumor microenvironment (TME), as well as tumor cell
escape. Dr. Ferris’s NIH-funded laboratory is focused on reversal of immune escape and immunotherapy using monoclonal antibodies and vaccines, leading to the first positive randomized phase III trial of head and cancer immunotherapy. He is Principal Investigator of the Pitt Specialized Program of Research Excellence (SPORE) grant for translational head and neck research and has been continuously NIH R01 funded for >15 years.

Dr. Ferris has an h-index of 96 and his >420 peer-reviewed scientific and clinical publications have garnered >36,000 citations. Dr. Ferris currently serves on the Editorial Boards of JNCI, JCO, Clinical Cancer Research, and Cancer Immunology Research. He is Editor in Chief of Oral Oncology. He is lead investigator of several practice-changing, prospective randomized trials, including Checkmate-141 published in NEJM, which led to the FDA approval of Nivolumab for head and neck cancer, ECOG 3311 (published in JCO in late 2021), testing radiation dose-deintensification after transoral robotic surgery (TORS) for HPV+ oropharynx cancer, as well as ECOG ACRIN 3132, using p53 mutational testing in HPVnegative cancer, to predict response to radiation versus chemoradiation. He recently completed a 6-year term co-chairing  the NCI Steering Committee for Head and Neck Cancer and is currently Vice President of the American Head and Neck Society.

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.